No association of MDM2 SNP309 with risk of glioblastoma and prognosis

被引：0
作者：
Soufiane El Hallani
Yannick Marie
Ahmed Idbaih
Mathieu Rodero
Blandine Boisselier
Florence Laigle-Donadey
François Ducray
Jean-Yves Delattre
Marc Sanson
机构：
[1] INSERM,Faculté de Médecine
[2] U711,Laboratoire d’Immunologie Cellulaire
[3] Biologie des Interactions Neurones & Glie,undefined
[4] Université Pierre et Marie Curie,undefined
[5] AP-HP,undefined
[6] Groupe Hospitalier Pitié-Salpêtrière,undefined
[7] Service de Neurologie Mazarin,undefined
[8] INSERM U543,undefined
来源：
Journal of Neuro-Oncology | 2007年 / 85卷
关键词：
Glioblastoma; MDM2; Polymorphism; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.
引用
收藏
页码：241 / 244
页数：3
相关论文
共 191 条
[81]  
Bozkurt B(undefined)undefined undefined undefined undefined-undefined
[82]  
Akilli-Ozturk O(undefined)undefined undefined undefined undefined-undefined
[83]  
Kaya HS(undefined)undefined undefined undefined undefined-undefined
[84]  
Gur-Dedeoglu B(undefined)undefined undefined undefined undefined-undefined
[85]  
Yulug IG(undefined)undefined undefined undefined undefined-undefined
[86]  
Wilkening S(undefined)undefined undefined undefined undefined-undefined
[87]  
Bermejo JL(undefined)undefined undefined undefined undefined-undefined
[88]  
Burwinkel B(undefined)undefined undefined undefined undefined-undefined
[89]  
Klaes R(undefined)undefined undefined undefined undefined-undefined
[90]  
Bartram CR(undefined)undefined undefined undefined undefined-undefined
45678910111213